<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057546</url>
  </required_header>
  <id_info>
    <org_study_id>21-3590</org_study_id>
    <nct_id>NCT05057546</nct_id>
  </id_info>
  <brief_title>Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)</brief_title>
  <official_title>Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate changes in blood vessels around the heart (e.g., aorta and carotid&#xD;
      arteries) and in the brain with the loss of female sex hormones (e.g., estrogen) during the&#xD;
      menopause transition. The menopause transition is associated with declines in blood vessel&#xD;
      function and increased risk for cardiovascular disease and Alzheimer's disease. Increasing&#xD;
      evidence supports an early role for declines in blood vessel function and future development&#xD;
      of Alzheimer's disease in aging men and women. This study will learn about the effects of&#xD;
      changes in female sex hormones, such as estrogen, during the menopause transition on blood&#xD;
      vessel around the heart and in the brain in women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>BESH clinical trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aortic stiffness and pulsatile hemodynamics</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Aortic characteristic impedance and forward pressure wave amplitude</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Common carotid artery stiffness and pulsatile hemodynamics</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Carotid characteristic impedance and forward pressure wave amplitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular cerebral blood flow</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Cerebral blood flow measured by transcranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular cerebrovascular reserve</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Breath hold index measured by transcranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular cerebral blood flow</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Cerebral blood flow measured by Arterial Spin Labeling Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Menopause</condition>
  <condition>Estrogen Deficiency</condition>
  <condition>Women</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Premenopausal Group: GnRH antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)</description>
    <arm_group_label>Premenopausal Group: GnRH antagonist</arm_group_label>
    <other_name>Degarelix acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Healthy premenopausal and postmenopausal women will be recruited.&#xD;
        Premenopausal women will have regular menstrual cycles, with no change in observed cycle&#xD;
        length (21-35 days), confirmed by menstrual cycle calendars. Postmenopausal women will have&#xD;
        gone through natural (i.e., non-surgical) menopause with &gt;12 months but &lt;6 years of&#xD;
        amenorrhea. We will make a major effort to ensure that the women enrolled in this study&#xD;
        come from all races and ethnicities and a wide range of socioeconomic and educational&#xD;
        levels.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Seated resting blood pressure &gt;140/90 mmHg&#xD;
&#xD;
          -  Use of medications that might influence cardiovascular function or cerebral blood&#xD;
             flow;&#xD;
&#xD;
          -  Pregnant, currently breastfeeding or intention to become pregnant in the next 6&#xD;
             months;&#xD;
&#xD;
          -  Use of menopausal therapy or hormonal contraceptives, etc. within the previous 3&#xD;
             months or intent to start during the study period;&#xD;
&#xD;
          -  BMI &gt;39 kg/m2;&#xD;
&#xD;
          -  Vigorous intensity exercise &gt;2 days per week;&#xD;
&#xD;
          -  Any current or past history of systemic illness that would interfere with study&#xD;
             outcomes such as: diabetes, cancer (other than melanoma), liver, gallbladder disease,&#xD;
             peripheral artery disease or thromboembolism, neurological disease, CVD or&#xD;
             cerebrovascular disease;&#xD;
&#xD;
          -  Abnormal thyroid, liver, or kidney function testing during the screening examination&#xD;
             or bloodwork;&#xD;
&#xD;
          -  Plasma glucose &gt;126 mg/dl under fasting conditions;&#xD;
&#xD;
          -  Smoking or living with a smoker within the past 12 months;&#xD;
&#xD;
          -  Current or planned participation in an interventional study during the present study&#xD;
             or unwillingness to complete study-related procedures;&#xD;
&#xD;
          -  Patients who report active acute systemic infection (e.g., flu, common cold, etc),&#xD;
             fever (&gt; 100.0 °F) or feeling ill will be asked to delay vascular testing until they&#xD;
             are no longer febrile or ill. Additionally, anyone who has experienced a serious&#xD;
             illness (requiring hospitalization) within the last 6 months, had a confirmed positive&#xD;
             COVID test and hospitalized, or anyone with a confirmed positive COVID test within the&#xD;
             last 6 months will be ineligible to participate (discretion of the study PI and MD).&#xD;
&#xD;
          -  No use of vitamin/supplements or chronic use of anti-inflammatory medications, or&#xD;
             willingness to stop 1 month prior to the vascular visit.&#xD;
&#xD;
        In premenopausal women participating in the intervention:&#xD;
&#xD;
          -  Contraindications to Degarelix including hypersensitivity to degarelix acetate,&#xD;
             extrinsic peptide hormones, mannitol, GnRH, benzyl alcohol (the vehicle for injection&#xD;
             of degarelix acetate)&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
&#xD;
          -  Osteopenia or osteoporosis (i.e., proximal femur or lumbar spine DXA T scores &lt;-1.0)&#xD;
&#xD;
          -  CES-D score ≥16 (unless clinician follow-up and clinical judgement determine they are&#xD;
             eligible (will be noted in study chart)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyndsey DuBose, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver Anschutz Medical Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyndsey DuBose, PhD</last_name>
    <phone>720-848-5596</phone>
    <email>lyndsey.dubose@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerrie Moreau, PhD</last_name>
    <phone>(303)724-1914</phone>
    <email>kerrie.moreau@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsey DuBose, PhD</last_name>
      <phone>720-848-5596</phone>
      <email>lyndsey.dubose@cuanschutz.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

